Form 4: Janux Therapeutics Director Jay Lichter Reports Stock Transactions

Director Jay Lichter reports multiple transactions involving Janux Therapeutics common stock and stock options on September 13, 2024.

Summary

• On September 13, 2024, Jay Lichter, a director of Janux Therapeutics, reported several transactions involving the company's common stock.
• These transactions included the exercise of stock options at prices of $17, $10.73, $13.22, and $39.8, resulting in the acquisition of 1,868, 778, 778, and 391 shares, respectively.
• Lichter also reported the disposition of 3,815 shares of common stock at a price of $46.68.
• Following these transactions, Lichter directly owns 7,000 shares of common stock.
• Lichter also indirectly owns 2,959,175 shares through Avalon Ventures XI, L.P., 573,227 shares through Avalon BioVentures I, LP, and 3,021,414 shares through Avalon BioVentures SPV I, L.P.
• The report also amends previous Form 4 filings from September 30, 2024, and October 18, 2024, to reflect these transactions.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the biopharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting insider transactions, ensuring transparency in the market.
• Similar filings are made by directors and officers of other publicly traded biotech companies like Amgen, Gilead, and Regeneron.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they reflect insider activity.
• The filing ensures transparency for all stakeholders regarding insider trading activities.

Key Dates